Publications by authors named "Torsten Dreier"

Claim this Profile
T
The NHance Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients.
Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Philippe Barthélémy, Christophe Borg, Torsten Dreier

Biomedicines· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.
Adrian C Newland, Blanca Sánchez-González, László Rejtő, Miklos Egyed, Nataliya Romanyuk, Torsten Dreier

Am J Hematol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
James F Howard, Vera Bril, Ted M Burns, Renato Mantegazza, Malgorzata Bilinska, Torsten Dreier

Neurology· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.
Peter Ulrichts, Antonio Guglietta, Torsten Dreier, Tonke van Bragt, Valérie Hanssens

J Clin Invest· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.
Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Fritz Offner, Dominique Bron, Torsten Dreier

Clin Cancer Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions.
Els Beirnaert, Aline Desmyter, Silvia Spinelli, Marc Lauwereys, Lucien Aarden, Torsten Dreier

Front Immunol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining somatic mutations present in different in vivo affinity-matured antibodies isolated from immunized Lama glama yields ultra-potent antibody therapeutics.
Alex Klarenbeek, Christophe Blanchetot, Georg Schragel, Ava S Sadi, Nico Ongenae, Torsten Dreier

Protein Eng Des Sel· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
Anna Hultberg, Virginia Morello, Leander Huyghe, Natalie De Jonge, Christophe Blanchetot, Torsten Dreier

Cancer Res· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade.
Karen Silence, Torsten Dreier, Mahan Moshir, Peter Ulrichts, Sofie M E Gabriels

MAbs· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Four individually druggable MET hotspots mediate HGF-driven tumor progression.
Cristina Basilico, Anna Hultberg, Christophe Blanchetot, Natalie de Jonge, Els Festjens, Torsten Dreier

J Clin Invest· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology.
Bernard M Tijink, Toon Laeremans, Marianne Budde, Marijke Stigter-van Walsum, Torsten Dreier

Mol Cancer Ther· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis.
Ken Coppieters, Torsten Dreier, Karen Silence, Hans de Haard, Marc Lauwereys

Arthritis Rheum· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Bernd Schlereth, Cornelia Quadt, Torsten Dreier, Peter Kufer, Grit Lorenczewski

Cancer Immunol Immunother· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells.
Juergen M Schanzer, Patrick A Baeuerle, Torsten Dreier, Peter Kufer

Cancer Immun· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo.
Marcel Zocher, Patrick A Baeuerle, Torsten Dreier, Antonio Iglesias

Int Immunol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
Pauline Wimberger, Wei Xiang, Doris Mayr, Joachim Diebold, Torsten Dreier

Int J Cancer· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells.
Wei Xiang, Pauline Wimberger, Torsten Dreier, Joachim Diebold, Doris Mayr

J Cancer Res Clin Oncol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct.
Torsten Dreier, Patrick A Baeuerle, Iduna Fichtner, Michael Grün, Bernd Schlereth

J Immunol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.
Torsten Dreier, Grit Lorenczewski, Christian Brandl, Patrick Hoffmann, Uwe Syring

Int J Cancer· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment.
Stefanie Naundorf, Susanne Preithner, Petra Mayer, Sandra Lippold, Andreas Wolf, Torsten Dreier

Int J Cancer· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis